Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) – Drugs In Development, 2024 report and make more profitable business decisions.
Chronic Cutaneous Lupus Erythematosus also known as discoid lupus is a group of autoimmune disorders affecting the major areas of skin that can be associated with SLE. CLE is classified as acute, subacute, intermittent, and chronic. Although the cause is unknown major concerns are genetic, innate, and adaptive immune responses, smoking, exposure to sun, and medications. Upon physical examination round, coin-shaped lesions are observed specifically butterfly rash over cheeks that can be itchy or non-itchy. A skin biopsy is done for diagnosis. If untreated it can result in CKD that leads to transplantation, anemia, immunological effects, CNS effects seizures can be seen. Steroids are primary regimens given topically or through systemic route and symptomatic treatment. Prevention is decreased exposure to sun, or triggering factors, use of sunscreen lotion and vitamin D supplements recommended.
The Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) drugs in development market research report provide comprehensive information on the therapeutics under development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 12 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AstraZeneca PlcBiogen Inc
Bristol-Myers Squibb Co
Cipher Pharmaceuticals Inc
GSK plc
Horizon Therapeutics Plc
Incyte Corp
Merck KGaA
Pfizer Inc
Tianjin Institute of Pharmaceutical Research
viDA Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions